// App-Quantinova.ai

: A Prospective Analysis of Breakthrough Hemolysis in 2 Phase 3 Randomized Studies of Ravulizumab (ALXN1210) Versus Eculizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria

Researchers

Presenter

  • Robert A. Brodsky

Principal Investigators

  • Regis Peffault De Latour

  • Scott T. Rottinghaus

  • Alexander Rth

  • Antonio M. Risitano

  • Ilene C. Weitz

  • Peter Hillmen

  • Jaroslaw P. Maciejewski

  • Jeffrey Szer

  • Jong-Wook Lee

  • Austin G. Kulasekararaj

  • Lori Volles

  • Andrew I. Damokosh

  • Stephan Ortiz

  • Lori Shafner

  • Anita Hill

  • Hubert Schrezenmeier

Medical Centers

  • Division of Surgical Oncology, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD

  • Universite Paris Descartes, Paris, France

  • French Reference Center for Aplastic Anemia and PNH Hematology-Bone Marrow Transplantation, Research Institute for Microbial Diseases, Hôpital Saint-Louis AP-HP, Paris, France

  • Alexion Pharmaceuticals Inc., New Haven, CT

  • Department of Surgery, University Hospital Essen, Essen, Germany

  • Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy

  • Jane Anne Nohl Division of Hematology, Keck School Of Medicine of USC, Los Angeles, CA

  • Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

  • Clinical Haematology, Royal Melbourne Hospital, Melbourne, Australia

  • Department of Laboratory Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of

  • Department of Haematological Medicine,King’s College Hospital, NIHR/Wellcome King’s Clinical Research Facility,London,United Kingdom

  • Paediatric Haematology,Leeds Teaching Hospitals,Leeds,United Kingdom

  • Institute for Clinical Transfusion Medicine and Immunogenetics Ulm German Red Cross Blood Service Baden-Wurttemberg, University Hospital Ulm, Ulm, Germany

  • Institute of Transfusion Medicine, University of Ulm, Germany ,

Locations

  • United States

  • France

  • Germany

  • Italy

  • United Kingdom

  • Australia

  • Republic of South Korea

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Paroxysmal nocturnal hemoglobinuria

Biomarkers

  • Lactate dehydrogenase

Drug/Treatment

  • Eculizumab

  • ALXN-1210

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Non Inferiority

  • Multicenteric

  • Prospective

Phase

  • III

Study Id's

  • NCT02946463

  • NCT03056040

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved